BioCentury
ARTICLE | Clinical News

Cancer Therapeutics CRC preclinical data

April 9, 2012 7:00 AM UTC

In a mouse model of TNBC, 80 mg/kg oral CTX-0294945 plus Avastin bevacizumab inhibited tumor growth by 88% at day 28 compared to 75% for Avastin alone. At day 28, tumors in mice receiving vehicle or ...